Advisors Preferred’s AbbVie ABBV Stock Holding History

Advisors Preferred’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,031	Closed	-$346K	–	185
2024 Q2	$346K	Buy	+2,031	New	+$336K	0.06%	100
2023 Q3	–	Sell	-3,660	Closed	-$494K	–	196
2023 Q2	$494K	Buy	3,660 +654	+22%	+$95.9K	0.12%	65
2023 Q1	$482K	Sell	3,006 -672	-18%	-$103K	0.17%	75
2022 Q4	$597K	Sell	3,678 -240	-6%	-$36.8K	0.25%	51
2022 Q3	$541K	Sell	3,918 -519	-12%	-$74.5K	0.28%	53
2022 Q2	$680K	Buy	+4,437	New	+$678K	0.18%	51
2021 Q2	–	Sell	-9,442	Closed	-$1.02M	–	183
2021 Q1	$1.02M	Buy	+9,442	New	+$1.01M	0.15%	52
2019 Q4	–	Sell	-216	Closed	-$16K	–	226
2019 Q3	$16K	Sell	216 -1,717	-89%	-$118K	﹤0.01%	182
2019 Q2	$142K	Buy	+1,933	New	+$152K	0.05%	94
2016 Q2	–	Sell	-46	Closed	-$3K	–	213
2016 Q1	$3K	Sell	46 -154	-77%	-$8.58K	﹤0.01%	197
2015 Q4	$12K	Buy	+200	New	+$11.5K	0.01%	171
2015 Q2	–	Sell	-155	Closed	-$9.07K	–	206
2015 Q1	$9.07K	Sell	155 -1,205	-89%	-$72.8K	﹤0.01%	231
2014 Q4	$89K	Buy	+1,360	New	+$85.7K	0.04%	186

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Advisors Preferred's ABBV Position: Q3 2024 in Review

Advisors Preferred sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 2,031 shares — an estimated $346K sold.

Advisors Preferred first reported a position in ABBV in Q4 2014 and held it in 13 quarters. The position peaked at $1.02M in Q1 2021. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Advisors Preferred reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
Advisors Preferred sold 2,031 AbbVie shares in Q3 2024, an estimated $346K.
Advisors Preferred first reported a position in AbbVie in Q4 2014 and held it in 13 quarters.
Advisors Preferred's AbbVie position peaked at $1.02M in Q1 2021.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Advisors Preferred's 13F filing for Q3 2024, filed 15 Oct 2024.